Evidence map›Paper›PMID 39856052›Full record

ArticleNature communications2025

NKp46 enhances type 1 innate lymphoid cell proliferation and function and anti-acute myeloid leukemia activity.

Rui Ma, Zhenlong Li, Hejun Tang, Xiaojin Wu, Lei Tian, Zahir Shah, Ningyuan Liu, Tasha Barr, Jianying Zhang, Sean Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rui Ma *Center for Molecular Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zhenlong Li *Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, 91010, USA.ORCID http://orcid.org/0009-0005-1171-4070
Hejun Tang *Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, 91010, USA.
Xiaojin Wu *The First Affiliated Hospital of Soochow University, Suzhou, 215005, China.
Lei TianDivision of Hematology & Oncology, Department of Medicine, School of Medicine, University of California, Irvine, CA, 92697, USA.
Zahir ShahDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, 91010, USA.
Ningyuan LiuDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, 91010, USA.
Tasha BarrDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, 91010, USA.ORCID http://orcid.org/0000-0003-1404-7830
Jianying ZhangDepartment of Computational and Quantitative Medicine, City of Hope National Medical Center, Los Angeles, CA, 91010, USA.
Sean WangDivision of Transfusion Medicine, City of Hope National Medical Center, Los Angeles, CA, 91010, USA.
Srividya SwaminathanDepartment of Systems Biology, City of Hope Beckman Research Institute, Los Angeles, CA, 91010, USA.ORCID http://orcid.org/0000-0002-3459-7488
Guido MarcucciGehr Family Center for Leukemia Research, Hematologic Malignancies Research Institute, Department of Hematological Malignancies Translational Science, City of Hope National Medical Center, Los Angeles, CA, 91010, USA.ORCID http://orcid.org/0000-0002-3983-5908
Yong PengCenter for Molecular Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China. yongpeng@scu.edu.cn.ORCID http://orcid.org/0000-0002-1181-3467
Michael A CaligiuriDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, 91010, USA. mcaligiuri@coh.org.ORCID http://orcid.org/0000-0002-4095-3020
Jianhua YuDivision of Hematology & Oncology, Department of Medicine, School of Medicine, University of California, Irvine, CA, 92697, USA. jianhuay@uci.edu.ORCID http://orcid.org/0000-0002-0326-3223

Funding

Human natural killer cells: Advancing biology and clinical applicationsR35CA210087 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2017 to 2026
$8.3M
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaR01CA265095 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BUDDE, LIHUA ELIZABETH, CALIGIURI, MICHAEL A · 2021 to 2025
$2.4M
California Institute for Regenerative Medicine (CIRM) DISC2-14190California Institute for Regenerative Medicine (CIRM) TRAN1-14003California Institute for Regenerative Medicine (CIRM) TRAN1-14716Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) CA210087Leukemia and Lymphoma Society (Leukemia & Lymphoma Society) 1364-19NCI NIH HHS R01 CA265095NCI NIH HHS R35 CA210087
6 · The paper itself

Abstract

NKp46 is a critical regulator of natural killer (NK) cell immunity, but its function in non-NK innate immune cells remains unclear. Here, we show that NKp46 is indispensable for expressing IL-2 receptor-α (IL-2Rα) by non-NK liver-resident type-1 innate lymphoid cells (ILC1s). Deletion of NKp46 reduces IL-2Rα on ILC1s by downregulating NF-κB signaling, thus impairing ILC1 proliferation and cytotoxicity in vitro and in vivo. The binding of anti-NKp46 antibody to NKp46 triggers the activation of NF-κB, the expression of IL-2Rα, interferon-γ (IFN-γ), tumor necrosis factor (TNF), proliferation, and cytotoxicity. Functionally, NKp46 expressed on mouse ILC1s interacts with tumor cells through cell-cell contact, increasing ILC1 production of IFN-γ and TNF, and enhancing cytotoxicity. In a mouse model of acute myeloid leukemia, deletion of NKp46 impairs the ability of ILC1s to control tumor growth and reduces survival. This can be reversed by injecting NKp46

Indexed as

Antigens, LyImmunity, InnateLeukemia, Myeloid, AcuteLymphocytesNatural Cytotoxicity Triggering Receptor 1AnimalsCell Line, TumorCell ProliferationCytotoxicity, ImmunologicHumansInterferon-gammaKiller Cells, NaturalLiverMiceMice, Inbred C57BLMice, KnockoutAntigens, LyInterferon-gammaNatural Cytotoxicity Triggering Receptor 1Ncr1 protein, mouseNF-kappa BTumor Necrosis Factor-alpha

Identifiers

PMID39856052
PMCPMC11760942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.